New Research Shows the Use of Fixed Dose Combination (FDC) Therapy will Continue to Grow Substantially Exceeding the Growth of Single Pill Alternatives

Dublin (PRWEB) April 14, 2006 -- Research and Markets (http://www.researchandmarkets.com/reports/c35602) has announced the addition of “Antihypertensives - Weak Pipeline Leaves Innovation to Novartis” to their offering

Despite modest improvements in blood pressure control, effective blood pressure control for all still seems to be an elusive goal. As such, the promotion and use of combination therapies has increased, explaining much of the current R&D activity in this area where many developers are studying novel combinations of currently marketed drugs rather than discovering innovative treatments

This report evaluates patient potential for developmental antihypertensives over the period 2006-2015 and scrutines the key impacts on the R&D approach and cost. The report evaluates optimal clinical trial end points and identifies suitable comparators. Also provided in the report is an evaluation of key players in the hypertensive market and opposing company approaches to development and commercialization. An analysis of key antihypertensive drugs in development and their ability to satisfy major unmet needs and compete with existing agents is provided.

The use of fixed dose combination (FDC) therapy will continue to grow substantially over the forecast period, exceeding the growth of single pill alternatives. Despite FDCs forming an essential part of a strategy for controlling hypertension, their development is starving innovation within antihypertensive R&D

Rasilez, the only real innovation in the current pipeline, will be the first oral renin inhibitor to be launched. Its ability to proximally block the renin angiotensin system (RAS), combined with its true 24-hour activity, means it may offer specific advantages over other drug classes, and is likely to become a blockbuster by 2010

Despite continued research into other hypertension targets such as endothelin and vasopeptidase poor safety records, lack of efficacy compared to other classes and a low patient potential, these agents promise to be no more than an academic interest rather than providing physicians with a real alternative in treating hypertension

With this report you can understand physician sentiment on renin inhibitors as the next innovative drug class, and the threats faced by existing and developmental products. The report enables you to view independent sales forecasts for products in late stage development for treatment of hypertension in both existing and novel classes. After reading this report you will be able to identify early stage antihypertensive compounds with high potential being developed by companies seeking a marketing partner.

For more information visit http://www.researchandmarkets.com/reports/c35602
Source: Datamonitor

Laura Wood
Senior Manager
Research and Markets
Fax: +353 1 4100 980

###